Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
Collegium Pharmaceutical (COLL) is set to announce its fourth-quarter and full-year 2025 results on February 26. The company's revenue growth is expected to be driven by its ADHD drug Jornay PM and its portfolio of pain medications, Belbuca, Xtampza ER, Nucynta IR, and Nucynta ER. Despite a history of beating earnings estimates, Zacks' model does not predict a beat for COLL this quarter, largely due to a negative Earnings ESP.
Collegium Pharmaceutical, Inc. (COLL) Gains Momentum on Jornay PM, Truist Highlights Robust Pain Portfolio
Truist Securities analyst Les Sulewski raised the price target for Collegium Pharmaceutical (COLL) to $58 from $55, maintaining a Buy rating, citing the strength of its pain management portfolio and momentum with Jornay. Collegium expects net product revenue between $805 million and $825 million for 2026, with Jornay PM projected to contribute at least $190 million to $200 million in net sales. The company also anticipates adjusted EBITDA to range from $455 million to $475 million, signaling strong profitability and sustained earnings growth.
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, before market open. Following the release, the company will host a live conference call and webcast at 8:00 a.m. ET. Collegium is a biopharmaceutical company focusing on pain management and neuropsychiatry, with Jornay PM® as a key growth driver.
(COLL) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Collegium Pharmaceutical Inc. (NASDAQ: COLL), highlighting weak near-term sentiment despite potential long-term strength. It details specific institutional trading strategies across different risk profiles, including long-term position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis aims to offer actionable insights and risk management parameters for investors.
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, before the market opens. Following the release, the company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results. Collegium focuses on diversified biopharmaceuticals, with a portfolio including pain management and a rapidly growing neuropsychiatry business, primarily driven by Jornay PM for ADHD.
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, before market open. The company will subsequently host a live conference call and webcast at 8:00 a.m. ET to discuss the results. Collegium focuses on diversified biopharmaceuticals, with a portfolio including pain management and a rapidly growing neuropsychiatry business, specifically Jornay PM® for ADHD.
The Truth About Collegium Pharmaceutical (COLL): Quiet Stock, Loud Moves – Are You Sleeping On Thi
Collegium Pharmaceutical (COLL) is presented as a "quiet stock" in the pain-drug market, emphasizing its focus on branded, extended-release pain medications rather than trending hype. The article suggests that while it lacks social media virality, COLL generates substantial cash flow, paying down debt and returning value to shareholders, making it a potential "sneaky must-have" for investors who prioritize fundamentals over speculative growth, despite risks in regulation and litigation.
Truist Securities raises Collegium Pharmaceutical stock price target to $58 By Investing.com
Truist Securities has increased its price target for Collegium Pharmaceutical (NASDAQ:COLL) to $58.00 from $55.00, reiterating a Buy rating. This adjustment follows positive meetings with Collegium management concerning Jornay PM's growth and the opioid market, with analysts noting greater durability in Collegium's pain franchise than market expectations. Additionally, Collegium recently closed a new $980 million syndicated credit facility, enhancing its financial flexibility.
Truist Securities raises Collegium Pharmaceutical stock price target to $58
Truist Securities has increased its price target for Collegium Pharmaceutical (NASDAQ:COLL) to $58 from $55, maintaining a Buy rating. This adjustment follows positive meetings with Collegium management regarding the growth of Jornay PM and the company's pain portfolio, as well as recent news of Collegium closing a new $980 million syndicated credit facility to enhance financial flexibility.
Versor Investments LP Purchases New Position in Collegium Pharmaceutical, Inc. $COLL
Versor Investments LP has acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL), purchasing 38,201 shares valued at approximately $1.34 million. This move represents about 0.12% ownership in the company. Concurrently, several insiders, including EVP Scott Dreyer and Director Rita J. Balice-Gordon, have sold shares, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $52.80.
Principal Financial Group Inc. Cuts Holdings in Collegium Pharmaceutical, Inc. $COLL
Principal Financial Group Inc. reduced its stake in Collegium Pharmaceutical, Inc. by 10.7% in Q3, selling 157,104 shares to own 1,309,771 shares valued at $45.8 million, representing 4.16% of the company. Despite insider selling, Collegium Pharmaceutical reported strong quarterly earnings, beating analyst estimates, and currently holds a "Moderate Buy" consensus rating with a $52.80 average price target from analysts. The specialty pharmaceutical company, known for its pain management products, shows solid financial metrics including a market cap of $1.52 billion and a P/E ratio around 29.9.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from Brokerages
Collegium Pharmaceutical (NASDAQ:COLL) has received an average rating of "Moderate Buy" from seven brokerages, with five recommending a "buy" and two a "hold." The average one-year target price among analysts is $52.80, and several firms recently raised their price targets. The company recently beat quarterly EPS and revenue estimates, though revenue was down year-over-year.
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation
Collegium Pharmaceutical Inc (NASDAQ:COLL) is highlighted as a strong value investing opportunity due to its high earnings and exceptionally low valuation. Despite some financial concerns like a high debt-to-equity ratio and a non-existent dividend, its robust earnings scores and cash flow generation suggest it may offer a "margin of safety" for investors willing to look past its average growth outlook. The article advises further research for those interested in undervalued stocks.
What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders
Collegium Pharmaceutical recently reported a strong 31.40% past revenue growth, driven by its pain management products Xtampza ER and Belbuca, and has a relatively low forward P/E of 5.71. While its pain portfolio is expected to generate solid cash flows, the company faces risks associated with compressing profit margins and a substantial debt load from its US$980 million credit facility. Analyst fair value estimates for COLL shares vary widely, ranging from US$53.17 to US$240.35, indicating diverse investor perspectives given the company's margin pressure and elevated leverage.
What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders
Collegium Pharmaceutical recently reported a significant 31.40% revenue growth, driven by its pain management products Xtampza ER and Belbuca, and maintains a low forward P/E of 5.71. Despite this growth, the company faces challenges with compressing profit margins and high debt from a US$980 million credit facility. While the revenue surge provides some financial flexibility, the substantial debt load remains a key concern for investors.
What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders
Collegium Pharmaceutical recently reported a strong 31.40% revenue growth, driven by its pain management products, Xtampza ER and Belbuca, and a focus on abuse-deterrent formulations. Despite this growth and a low forward P/E of 5.71, the company faces compressing profit margins and weak interest coverage due to a significant debt load from a US$980 million credit facility. While the revenue surge might offer management more flexibility with the balance sheet, the substantial debt remains a critical concern for investors.
Ballast Asset Management LP Purchases 27,109 Shares of Collegium Pharmaceutical, Inc. $COLL
Ballast Asset Management LP increased its stake in Collegium Pharmaceutical, Inc. by 31.1%, acquiring 27,109 additional shares to now hold 114,315 shares valued at approximately $4.0 million. This makes Collegium Pharmaceutical the 26th biggest holding in Ballast Asset Management LP's portfolio, representing about 0.36% of the company. The move follows Collegium Pharmaceutical's recent strong quarterly earnings, beating EPS estimates, despite a year-over-year revenue decrease.
(COLL) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Collegium Pharmaceutical Inc. (NASDAQ: COLL), highlighting divergent sentiment and suggesting choppy conditions. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels for near-term, mid-term, and long-term horizons.
Collegium Pharmaceutical: Quiet Chart, Loud Questions Around This Specialty Pain Stock
Collegium Pharmaceutical's stock has shown stability over the past week, trading sideways, yet it raises questions about its valuation. While the company benefits from steady cash flows from chronic pain brands, it faces regulatory, reimbursement, and opioid litigation risks. Investors are currently weighing the company's consistent cash generation against these potential headwinds and absence of strong growth catalysts.
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL
Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 24.1% in Q3, selling over 30,000 shares. Despite this, other institutions increased their holdings, and the company reported strong Q3 earnings, exceeding both EPS and revenue estimates. Analysts maintain a "Moderate Buy" rating with an average target price of $52.80, even as insiders have sold a significant number of shares recently.
Emerald Mutual Fund Advisers Trust Sells 154,973 Shares of Collegium Pharmaceutical, Inc. $COLL
Emerald Mutual Fund Advisers Trust reduced its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 28.1% in Q3 2025, selling 154,973 shares and ending the quarter with 395,661 shares valued at $13.84 million. Despite the reduction, the stock maintains a consensus "Moderate Buy" rating with an average price target of $52.80, and Collegium Pharmaceutical beat its quarterly EPS and revenue estimates. Several other institutional investors increased their positions in the company, while company insiders sold 51,250 shares last quarter.
(COLL) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Collegium Pharmaceutical Inc. (NASDAQ: COLL), noting a neutral near and mid-term outlook but a strong long-term positive bias. It presents three distinct institutional trading strategies (Position, Momentum Breakout, Risk Hedging) and highlights an exceptional 41.5:1 risk-reward setup targeting a 12.1% gain. The piece also details multi-timeframe signal analysis and encourages users to access real-time signals and personalized alerts.
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pullback
Collegium Pharmaceutical (COLL) has seen a recent share price pullback but shows positive long-term momentum. The company is currently considered 14.2% undervalued with a narrative fair value of US$53.17 based on projected 2026 earnings and profitability, driven by disciplined capital allocation and an M&A growth strategy. However, its P/E ratio of 24.7x is higher than the peer average, suggesting it might be somewhat expensive despite the undervaluation.
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pullback
Collegium Pharmaceutical (COLL) has seen a recent share price pullback but shows strong long-term momentum. The company is considered undervalued with a narrative fair value of US$53.17 based on future earnings and strategic growth, despite its P/E ratio appearing somewhat expensive compared to peers. Investors should consider potential risks like patent expirations and fixed costs, alongside the company's M&A strategy for diversification.
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pullback
Collegium Pharmaceutical (COLL) has seen a recent share price pullback but shows positive momentum over longer periods, with its stock trading significantly below its narrative fair value of $53.17. While considered undervalued based on detailed earnings and profitability assumptions, its P/E ratio is higher than peers, suggesting it might be somewhat expensive from another viewpoint. Investors are encouraged to consider both the narrative valuation and earnings multiple, along with potential risks and capital allocation strategies.
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain?
Collegium Pharmaceutical (COLL) has seen a 40% gain over the past year, prompting investors to question its current value. Despite short-term declines, the stock shows strong multi-year returns. A Discounted Cash Flow analysis suggests COLL is significantly undervalued, while a Price-to-Earnings comparison indicates it might be overvalued relative to its "Fair Ratio."
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain?
Collegium Pharmaceutical (COLL) has seen a 40.2% gain over the past year, prompting investors to question its current valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 80.5% at US$46.90 per share, its P/E ratio of 25.37x is above the industry average and its proprietary "Fair Ratio" of 23.38x, indicating it might be overvalued on that metric. The article encourages investors to use valuation narratives on Simply Wall St's community page to align their views with specific forecasts and fair values.
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain?
Collegium Pharmaceutical (COLL) has seen a significant 40.2% gain over the past year, prompting investors to assess its current valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 80.5% at around $46.90 per share, its Price-to-Earnings (P/E) ratio of 25.37x is above the industry average, indicating it might be overvalued by this metric. The article encourages investors to consider multiple valuation approaches and utilize tools like "Narratives" for a personalized assessment.
Eastern Bank Buys 45,508 Shares of Collegium Pharmaceutical, Inc. $COLL
Eastern Bank significantly increased its stake in Collegium Pharmaceutical (NASDAQ:COLL) by 487.5% in Q3, now holding 54,843 shares valued at $1.919 million. Despite this, company insiders sold over 51,000 shares worth approximately $2.24 million in the last 90 days. Collegium Pharmaceutical beat Q3 earnings estimates with EPS of $2.25 and revenue of $209.4M, and analysts maintain a "Moderate Buy" rating with an average price target of $52.80.
Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL?
Collegium Pharmaceutical has released its 2026 revenue guidance, projecting net product revenues between US$805,000,000 and US$825,000,000. This guidance, provided after a significant stock price increase in 2025 and insider sales, offers insights into the company's outlook on its pain and ADHD treatments. While the guidance largely reinforces the existing investment narrative, investors should consider the impact of recent financing and future generic competition.
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Collegium Pharmaceutical, Inc. announced it will present four posters highlighting real-world data for its ADHD product, Jornay PM, at the APSARD 2026 Annual Conference. The presentations will cover topics such as optimal dosing, comparative risks and benefits against Concerta, and changes in functioning, depression, and anxiety severity in patients using Jornay PM. This aims to provide valuable insights for clinicians and the ADHD community to enhance clinical decision-making.
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
Collegium Pharmaceutical, Inc. announced it will present four poster presentations at the APSARD 2026 Annual Conference, highlighting real-world data for its ADHD product, Jornay PM. The presentations will cover topics such as optimal dosing, comparative risks and benefits against Concerta, and changes in functioning, depression, and anxiety severity in patients. This initiative underscores Collegium's commitment to generating real-world evidence to aid clinical decision-making and improve patient care for ADHD.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of "Moderate Buy" by Analysts
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received an average "Moderate Buy" rating from analysts, with an average 1-year price target of $52.80. The company recently issued 2026 guidance that exceeded consensus expectations, forecasting product revenues of $805M–$825M and adjusted EBITDA of $455M–$475M. Despite positive financial outlook and analyst endorsements, there has been notable insider selling, with the CFO and EVP collectively selling over 47,000 shares in the last quarter.
A Look At Collegium Pharmaceutical (COLL) Valuation After 2026 Guidance And Nucynta Authorized Generic Agreements
Collegium Pharmaceutical (COLL) has provided 2026 guidance, projecting net product revenue of US$805 million to US$825 million, alongside new Nucynta authorized generic agreements. Despite a recent share price pullback, its shares have seen significant returns over the past year. Analysts largely agree on future earnings growth, estimating the stock as modestly undervalued, although its P/E ratio is higher than industry and peer averages.
A Look At Collegium Pharmaceutical (COLL) Valuation After 2026 Guidance And Nucynta Authorized Generic Agreements
Collegium Pharmaceutical (COLL) is seeing its shares react to new 2026 guidance, projecting $805 million to $825 million in net product revenue, and recent Nucynta authorized generic agreements. The company's stock has seen significant returns over the past year, leading to a valuation discussion on whether it remains undervalued or if its growth is already priced in. While a valuation narrative suggests the stock is modestly undervalued at $48.67 compared to its current price of $45.54, its P/E ratio is higher than the industry average, signaling less margin for error.
How Good Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL), When It Comes To ROE?
Collegium Pharmaceutical's Return On Equity (ROE) is 21%, similar to the Pharmaceuticals industry average. While this is respectable, the company also has a high debt-to-equity ratio of 3.39, suggesting that debt contributes significantly to its ROE. Investors should consider both ROE and debt levels for a comprehensive understanding of the company's financial health.
How Collegium’s New $980 Million Credit Facility Could Reshape Collegium Pharmaceutical (COLL) Investors’ Risk Lens
Collegium Pharmaceutical (COLL) recently secured a new $980 million syndicated credit facility, maturing in 2030, which includes an initial term loan, a delayed draw term loan, and a revolver. This refinancing is expected to reduce annual interest costs and provide flexible borrowing capacity for corporate uses and business development, potentially reshaping its financial risk profile. While the stronger balance sheet offers some comfort, investors still need to consider looming patent expirations and potential generic competition.
$980M financing deal expected to save this drugmaker on interest
Collegium Pharmaceutical (COLL) has closed a new five-year, $980 million syndicated credit facility, maturing in 2030, aimed at significantly reducing interest expenses and providing financial flexibility. The facility includes an initial term loan used to repay a prior $581 million debt and also features undrawn delayed draw and revolving credit facilities for general corporate needs and business development. The company anticipates meaningful annualized interest savings due to the new attractive interest rate structure.
Collegium Provides 2026 Financial Guidance and Business Update
Collegium Pharmaceutical, Inc. announced its 2026 financial guidance, projecting product revenues between $805 million and $825 million, with Jornay PM net revenue expected to be $190 million to $200 million. The company anticipates adjusted EBITDA to range from $455 million to $475 million, driven by strong growth in its ADHD and pain portfolios, and a disciplined capital deployment strategy that includes debt reduction and potential business development. Collegium also highlighted its recent successful closing of a $980 million syndicated credit facility and an authorized generic agreement with Hikma Pharmaceuticals for Nucynta and Nucynta ER.
Collegium Provides 2026 Financial Guidance and Business Update
Collegium Pharmaceutical, Inc. announced its 2026 financial guidance, projecting product revenues between $805 million and $825 million, and adjusted EBITDA between $455 million and $475 million. The company expects Jornay PM® net revenue to be between $190 million and $200 million, driving significant growth. This update follows a strong 2025, buoyed by the performance of Jornay PM and recent refinancing efforts, positioning Collegium for continued expansion through commercial execution, strategic business development, and disciplined capital deployment.
How Collegium’s New $980 Million Credit Facility Could Reshape Collegium Pharmaceutical (COLL) Investors’ Risk Lens
Collegium Pharmaceutical (COLL) recently secured a new US$980 million credit facility, aimed at lowering annual interest costs and providing funding for corporate uses and potential business development. While this strengthens the balance sheet, investors should still consider looming patent expirations, generic competition, and the execution of their core product strategies. The facility supports the company's Q3 2025 guidance raise and could influence how investors weigh concentration risk against plans for portfolio expansion.
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Raises Target Price to $55
Truist Financial analyst Les Sulewski has maintained a Buy rating on Collegium Pharmaceutical (COLL.US) and increased the target price from $48 to $55. This adjustment is based on the analyst's track record of 54.0% success rate and an average return of 12.8% over the past year, as noted by TipRanks data. The information provided is for informational purposes and not an investment recommendation.
Exchange Traded Concepts LLC Reduces Holdings in Collegium Pharmaceutical, Inc. $COLL
Exchange Traded Concepts LLC significantly reduced its stake in Collegium Pharmaceutical, Inc. by 67.7% in Q3, now holding 21,067 shares worth $737,000. This comes amidst notable insider selling and other hedge funds adjusting their positions in the company. Collegium Pharmaceutical (NASDAQ:COLL) is trading at $49.48 with a "Buy" consensus rating and an average price target of $47.00.
Liquidity Mapping Around (COLL) Price Events
This article provides an in-depth liquidity mapping analysis for Collegium Pharmaceutical Inc. (NASDAQ: COLL), highlighting neutral near and mid-term readings that could influence a long-term positive bias. It details an exceptional risk-reward short setup, multiple institutional trading strategies including position, momentum breakout, and risk hedging, and multi-timeframe signal analysis generated by AI models.
Collegium Pharmaceutical Closes New $980 Million Credit Facility
Collegium Pharmaceutical has announced the closing of a new $980 million syndicated credit facility, maturing in 2030, to refinance existing debt and enhance financial flexibility. This new SOFR-based facility is expected to significantly reduce interest costs and support the company's long-term growth strategy, including portfolio expansion and diversification. Spark, TipRanks’ AI Analyst, rates COLL as Outperform, citing strong financial performance and positive earnings, while noting risks from valuation concerns and high leverage.
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the closing of a new $980 million syndicated credit facility, which matures in 2030 and significantly reduces interest rates, offering favorable terms. This financing includes a Term Loan used to repay previous debt, and a Delayed Draw Term Loan and revolving credit facility for general corporate purposes and future business development. The company expects meaningful annualized interest savings and increased flexibility for expanding its product portfolio.
Collegium Pharmaceutical Signs Credit Agreement With Truist Bank
Collegium Pharmaceutical secured a new senior credit agreement with Truist Bank, including a $580 million term loan, $300 million in delayed draw term loan commitments, and a $100 million revolver. The company used these funds to repay its previous loan facility and enhance its liquidity and flexibility. This refinancing replaces a prior agreement with Biopharma Credit which has now been terminated.
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical, Inc. has closed a new $980 million syndicated credit facility maturing in 2030, comprising a $580 million Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility. The initial Term Loan repaid the company's previous $646 million term loan, and the new facility's favorable terms are expected to significantly reduce interest rates for the company. This financing provides Collegium with capital flexibility to pursue business development and expand its product portfolio.
Collegium Pharmaceutical, Inc. Announces the Closing of $980 Million Syndicated Credit Facility
Collegium Pharmaceutical, Inc. secured a new $980 million syndicated credit facility, maturing in 2030, which includes an initial Term Loan, a Delayed Draw Term Loan, and a revolving credit facility. The initial Term Loan was used to repay $581 million of its previous debt, and the remaining funds are designated for general corporate purposes and future business development. This new facility is expected to result in significant annualized interest savings for the company.
Pacer Advisors Inc. Sells 87,066 Shares of Collegium Pharmaceutical, Inc. $COLL
Pacer Advisors Inc. has reduced its stake in Collegium Pharmaceutical, Inc. by 25.8%, selling 87,066 shares and retaining 250,601 shares valued at approximately $8.77 million. Despite this, analyst sentiment remains largely positive with an average "Buy" rating and a consensus target price of $47.00. However, company insiders have been net sellers in the past three months, offloading 51,250 shares for about $2.24 million.
